BeyondSpring Files 2020 Annual Report on Form 20-F
30 avr. 2021 08h00 HE
|
BeyondSpring, Inc.
NEW YORK, April 30, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative cancer...
BeyondSpring Announces Fourth Quarter and Year End 2020 Financial Results and Provides a Corporate Update
30 avr. 2021 07h00 HE
|
BeyondSpring, Inc.
- NDAs filed in the U.S. and China in Mar. 2021 based on superior data from Phase 3 PROTECTIVE-2 trial of Breakthrough Therapy Designation regimen, plinabulin plus G-CSF vs. G-CSF alone in prevention...
BeyondSpring Announces Five Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting
28 avr. 2021 16h37 HE
|
BeyondSpring, Inc.
- Four presentations to focus on the clinically meaningful endpoint improvement, including the reduction of febrile neutropenia and hospitalization, shown by plinabulin in the prevention of...
BeyondSpring to Announce Fourth Quarter and Year End 2020 Financial Results and Host a Conference Call on Friday, April 30, 2021
27 avr. 2021 11h22 HE
|
BeyondSpring, Inc.
NEW YORK, April 27, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer...
BeyondSpring Announces Submission of New Drug Application to U.S. FDA and China NMPA for Plinabulin and G-CSF Combination for the Prevention of Chemotherapy-Induced Neutropenia (CIN)
31 mars 2021 23h21 HE
|
BeyondSpring, Inc.
– Applications are supported by positive PROTECTIVE-2 Phase 3 data demonstrating that plinabulin in combination with G-CSF offers greater protection against CIN than the standard of care, G-CSF alone ...
BeyondSpring Hosting Key Opinion Leader Webinar on Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia
11 mars 2021 16h01 HE
|
BeyondSpring, Inc.
Webinar on Thursday, March 18th @ 10:00 a.m. ET NEW YORK, March 11, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical...
UPDATE -- BeyondSpring to Present at the J.P. Morgan Healthcare Conference on January 14, 2021
29 déc. 2020 09h19 HE
|
BeyondSpring, Inc.
NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer...
BeyondSpring to Present at the J.P. Morgan Healthcare Conference on January 14, 2021
29 déc. 2020 08h00 HE
|
BeyondSpring, Inc.
NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer...
BeyondSpring Announces the Appointment of Dr. Jeffrey Vacirca to its Board of Directors
17 déc. 2020 08h00 HE
|
BeyondSpring, Inc.
NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer...
BeyondSpring Announces New Positive PROTECTIVE-2 Phase 3 Registrational Trial Results at the 2020 San Antonio Breast Cancer Symposium
10 déc. 2020 08h00 HE
|
BeyondSpring, Inc.
- The plinabulin + pegfilgrastim combination reduces the incidence of profound neutropenia (ANC < 0.1 x 10E9 cells/L) by 53 % vs. pegfilgrastim alone - The plinabulin + pegfilgrastim combination...